DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Viroptic (Trifluridine Ophthalmic) - Published Studies


Viroptic Related Published Studies

Well-designed clinical trials related to Viroptic (Trifluridine Ophthalmic)

A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis. [1993.05]

Well-designed clinical trials possibly related to Viroptic (Trifluridine Ophthalmic)

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. [2012]

Slitlamp biomicroscopy and photographic image analysis of herpes simplex virus stromal keratitis. [2009.02]

Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis. [1995.08]

Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. [1994.12]

Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. [1994.12]

Phosphonoformate (foscarnet, PFA) versus trifluorthymidine in the treatment of keratitis dendritica in the human. A double-blind, randomized, preliminary trial. [1992.10]

Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration. [1991.11]

Bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration: a double blind controlled study. [1991]

[Epidemic keratoconjunctivitis: treatment results during an epidemic] [1990.09]

A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind, randomized parallel group trial. [1989.02]

An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. [1989]

Other research related to Viroptic (Trifluridine Ophthalmic)

[Trifluridine therapy in herpetic in keratitis] [2004.04]

Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. [1999.02]

Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. [1998.06]

Delivery of trifluridine to human cornea and aqueous using collagen shields. [1998.04]

Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. [1996.06.01]

Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents. [1991.08]

Trifluridine decreases ocular HSV-1 recovery, but not herpetic lesions after timolol iontophoresis. [1989.04]

Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. [1989]

Other possibly related research studies

Therapeutic interventions for herpes simplex virus epithelial keratitis. [2008.01.23]

Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. [2008.02]

Is herpes simplex virus keratitis a different disease in children? [2008.01]

Evidence-based treatment of herpes simplex virus keratitis: a systematic review. [2007.07]

Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. [2007.06]

Therapeutic interventions for herpes simplex virus epithelial keratitis. [2007.01.24]

The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. [2007.01.15]

Gateways to clinical trials. [2006.10]

Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. [2007.01]

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. [2006.09.15]

Corneal ulceration associated with naturally occurring canine herpesvirus-1 infection in two adult dogs. [2006.08.01]

Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. [2006]

Herpes simplex keratitis misdiagnosed as rheumatoid arthritis-related peripheral ulcerative keratitis. [2005.11]

Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. [2005.08]

Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. [2005.03]

Herpes simplex uveitis. [2004.03]

Ocular complications in the Department of Defense Smallpox Vaccination Program. [2004.11]

Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study. [2004.08]

Herpes simplex virus keratitis in children. [2004.09]

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. [2004.09]

[The latest in herpes simplex keratitis therapy] [2004.05]

Antiviral drugs in current clinical use. [2004.06]

Arthrographis keratitis mimicking acanthamoeba keratitis. [2004.04]

Ocular vaccinia following exposure to a smallpox vaccinee. [2004.03]

New onset of herpes simplex virus epithelial keratitis after penetrating keratoplasty. [2004.03]

Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. [2004.02]

Interventions for herpes simplex virus epithelial keratitis. [2003]

Ocular complications of smallpox vaccination. [2003.08]

In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. [2003.06]

Management of acyclovir-resistant herpes simplex virus. [2003.04]

The effect of roscovitine on herpetic keratitis. [2003.06]

Recurrence of keratitis after excimer laser keratectomy. [2003.01]

Atypical presentation of Acanthamoeba keratitis. [2001.10]

Efficacy of polyclonal antibodies for treatment of ocular herpes simplex infection. [2001.07]

Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits. [2001.07]

Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit. [2001.05]

Interventions for herpes simplex virus epithelial keratitis. [2001]

Contact dermatitis from topical antiviral drugs. [2001.05]

The treatment of herpes simplex virus epithelial keratitis. [2000]

Current recommendations for the treatment of genital herpes. [2000.12]

Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. [2000.08]

Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. [2000.05.15]

The impact of the herpetic eye disease studies on the management of herpes simplex virus ocular infections. [1999.08]

Cidofovir and experimental herpetic stromal disease. [1999.07]

[Herpetic keratitis. Clinical and therapeutic aspects] [1997]

Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group. [1996.11]

Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates. [1996.08]

Treatment of cats with ocular disease attributable to herpesvirus infection: 17 cases (1983-1993). [1995.09.01]

Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient. [1995.05]

Presumed ophthalmic herpes zoster after contralateral cataract extraction. [1995.02]

HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model. [1994.11]

Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. [1994.03]

Modulation of ricin toxicity in mice by biologically active substances. [1994.03]

Antivirals for the treatment of herpesvirus infections. [1993.07]

Topical immunoglobulins for epithelial herpes simplex keratitis. [1993]

Delayed onset of varicella keratitis. [1992.09]

Recurrent herpetic keratitis during topical acyclovir application. [1992.07]

Persistence of herpes simplex virus DNA in rabbit corneal cells. [1992.07]

Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. [1992.07]

A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing. [1992.03]

Potentiation of the antitumor activity of 5-trifluoromethyl-2'-deoxyuridine by the use of depot forms of the parent compound. [1992]

Cutaneous herpes simplex virus infections. [1991.05]

Herpes simplex dendritic keratitis after keratoplasty. [1991.04.15]

Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative. [1991]

Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents. [1991]

Use of collagen shields in the treatment of herpetic keratitis. [1991]

Emergence of cross-resistant herpes simplex virus following topical drug therapy in rabbit keratitis. [1991]

The development of corneal edema in herpes simplex virus type 1-infected rabbits following termination of therapy for corneal stromal disease. [1991]

Collagen shield delivery of trifluorothymidine. [1990.11]

Treatment of ocular disease in eczema herpeticum. [1990.09.15]

Comparative laboratory diagnosis of experimental herpes simplex keratitis. [1990.01.15]

New acquisitions in the chemotherapy of viral infections. [1990]

Herpes simplex keratitis in patients with acquired immune deficiency syndrome. [1989.10]

Evolution of therapy for cytomegalovirus infection. [1988.07]

Antiviral chemotherapy today and tomorrow. [1988]

Retinal toxicity of combination antiviral drugs in an animal model. [1987.10]

Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model. [1987.09]

Improved delivery through biological membranes XXV. Enhanced and sustained delivery of trifluorothymidine to the brain using a dihydropyridine in equilibrium pyridinium salt type redox delivery system. [1987.05]

Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model. [2008.10]

Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. [2008.11]

Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. [2008.10]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017